Hamilton Thomas Edward 4

What Happened Thomas Edward Hamilton, a director of Larimar Therapeutics, purchased 50,000 shares of LRMR in open-market transactions on July 6, 2026. The weighted-average price was $3.34 per share, for a total cost of approximately $166,890. This was a purchase (acquisition), which investors often view as more informative than routine sales, though the filing does not state any motive.

Key Details

• Transaction date: 2026-07-06 (reported on Form 4 filed 2026-07-08).
• Transaction type/code: Purchase (P) — open market/private purchase.
• Price: Weighted average $3.34; reported range $3.33–$3.35 (multiple trades). Footnote states the reporting person can provide a breakdown of trades/prices on request.
• Shares acquired: 50,000; total value ≈ $166,890.
• Shares owned after transaction: Not disclosed in this filing.
• Timeliness: Form 4 was filed two days after the transaction date (appears timely; no late-filing flag).

Context

• This was a straight stock purchase (no option exercise, grant, gift, or tax-withholding involved). Purchases by insiders can be interpreted by some investors as a positive signal, but the filing provides no explanation for the transaction.